Study Atlas
Study accountPrivacySaved locally

Internal Medicine

Non-viral hepatitis

Internal Medicine

Very High Yield30 min lesson estimate61 question families

Well covered in the main question banks · 32 main-bank entries · 68 linked PDF entries · 0 generated drills

Prerequisites and related lessons
  • Liver function tests (LFT)

Curriculum reference · Official College Textbook – Digestive Disorders – Part 2, pp. 115–130. Lesson adapted from Internal Medicine and Tropical Medicine.

Topic map

  • ImmuneAIH and cholestatic overlaps
  • IronHFE hemochromatosis and secondary overload
  • CopperATP7B Wilson disease
  • Other injuryalcohol, medication, hypoxic and inherited causes

Scroll the diagram to see all labels.

Three patterns of non-viral hepatic injuryIgG, iron studies and copper studies address different disease mechanisms.Liver Immune · IgG / ANAIron · saturationCopper · ATP7BInterface hepatitisTissue iron overloadBiliary export defect
Three patterns of non-viral hepatic injuryIgG, iron studies and copper studies address different disease mechanisms.

Recognizing non-viral injury

Non-viral causes include autoimmune, toxic/drug, alcohol-associated, metabolic, hypoxic and inherited liver disease. Start with exposure and family history, classify biochemical injury, assess INR/glucose and evaluate for viral causes and overlap as appropriate. In severe jaundice or INR rise assess decompensation. Drug injury may be hepatocellular or cholestatic; acetaminophen toxicity requires prompt toxicology assessment and N-acetylcysteine when indicated. Alcohol-associated hepatitis often presents with recent jaundice after prolonged heavy intake, AST greater than ALT, inflammation and nutritional risk. Abstinence and nutrition are central; selected severe cases can receive corticosteroids after contraindications are assessed, with response-guided stopping. Micronodular cirrhosis can occur with alcohol or biliary injury, but nodular morphology alone is nonspecific.

Autoimmune hepatitis and cholestatic overlap

Initial assessment
Characterize injury and assess severity; direct serology and metabolic tests
Confirmation or next test
Histology, genetics or targeted organ measurements when needed for the suspected cause

AIH is immune-mediated hepatocyte injury, often associated with other autoimmune conditions. The text quotes 75% female predominance [IM Dept Q1]. Presentations range from incidental ALT/AST elevation to fatigue, jaundice, cirrhosis or liver failure. Raised IgG/gamma globulins [IM Mid Q19/Q23 · IM Dept Q5] and type 1 ANA/SMA [IM Mid Q2 · IM Dept Q3] support AIH. Type 2 features anti-LKM1 targeting CYP2D6 [IM Dept Q2/Q4], sometimes with anti-LC1, and often presents younger. Interface hepatitis with plasma cells or piecemeal necrosis and portal fibrosis [IM Mid Q10 · IM Dept Q6] supports diagnosis after exclusion of mimics.

Marked ALP predominance [IM Mid Q13] is the exception for typical AIH. Assess overlap, especially cholestatic chemistry. AMA [IM Mid Q6] and raised IgM support primary biliary cholangitis, which injures small ducts and can cause pruritus. PSC is a separate inflammatory duct disease often linked to IBD, with multifocal strictures on cholangiographic assessment. Treat PBC with ursodeoxycholic acid when appropriate, and involve specialist care for PSC or variant syndromes.

AIH induction uses corticosteroids such as prednisolone and azathioprine as steroid-sparing maintenance [IM Dept Q7–8], individualized by severity and suitability. The exam’s 30 mg initial course figure is a regimen in the textbook, not a universal dose. Monitor ALT/AST, IgG, blood counts and adverse effects. The course quotes remission over 80% and possible withdrawal after 2–3 years of biochemical remission [IM Dept Q9–10]. Specialist criteria and relapse monitoring apply. Treatment-resistant disease can require alternatives such as mycophenolate or other specialist care. Budesonide is inappropriate in cirrhosis. Consider transplant for selected decompensated/severe cases.

Hemochromatosis and iron overload

HFE-related hereditary hemochromatosis is typically autosomal recessive [IM Mid Q7]. Dysregulated hepcidin increases intestinal iron absorption [IM Mid Q16] and tissue iron deposition. Secondary overload can occur with repeated transfusions or ineffective erythropoiesis. Symptoms include fatigue, arthralgia, hepatic enlargement/cirrhosis, skin pigmentation and diabetes [IM Mid Q18], hypogonadism or cardiomyopathy. Check transferrin saturation and ferritin [IM Mid Q3/Q18], which may be elevated with lower unsaturated binding capacity. Low serum iron is the EXCEPT. Ferritin also rises with inflammation and metabolic liver disease. Consider HFE testing, MRI iron quantification and fibrosis assessment when indicated. Treat appropriate primary iron overload with phlebotomy, with ferritin-guided monitoring. Use specialist chelation for selected secondary overload, and screen appropriate first-degree relatives.

Wilson disease

ATP7B on chromosome 13 [IM Mid Q22/Q24], autosomal recessive, causes defective biliary copper excretion [IM Mid Q9/Q15/Q20]. Liver, basal ganglia, cornea and kidneys may be affected; lung is the course exception. Young patients may show hepatitis/cirrhosis with tremor, dysarthria, dystonia or Kayser–Fleischer rings [IM Mid Q4/Q8/Q21]. Rings can be absent, require slit lamp and may fade after treatment. Circulating free copper can cause Coombs-negative hemolysis through oxidative damage [IM Mid Q5] in severe hepatic disease.

Assess low ceruloplasmin [IM Mid Q14], 24-hour urine copper, slit lamp, phenotype and ATP7B variants. Quantitative hepatic copper [IM Mid Q1] is the bank’s best confirmation among options, useful in selected unresolved cases. Combine results rather than treating one clue as decisive. Treat with specialist-directed chelation (trientine or D-penicillamine, with pyridoxine as indicated), or zinc in selected settings. Monitor copper balance and toxicity, screen relatives and urgently assess Wilson-related liver failure for transplant.

Exam traps

In liver disease plus diabetes and bronze skin, consider iron. In young liver disease plus movement symptoms and corneal rings, consider copper. AIH classically raises IgG. AMA and IgM point to PBC. A normal or low isolated copper measure does not exclude Wilson disease.

Diagnostic and management pathways

  • Identify hepatitic or cholestatic injury → assess acuity, synthesis and exposures
  • Order cause-directed IgG/antibodies, iron studies or copper/genetics → use biopsy/imaging when appropriate
  • Treat confirmed cause and monitor response/toxicity
  • Decompensation or acute failure → urgent specialist and transplant assessment

Compare at a glance

CauseHigh-yield patternManagement anchor
AIHHigh IgG, ANA/SMA or LKM1, interface activityImmunosuppression and monitoring
HemochromatosisHigh saturation/ferritin, iron tissue injuryPhlebotomy in appropriate primary disease
WilsonLow ceruloplasmin, urine copper and K–F ringsChelators or selected zinc, lifelong follow-up
PBCCholestatic enzymes, AMA and IgMUDCA and surveillance

Supplementary clarification – not directly stated in the uploaded materials. Clinical references · EASL autoimmune hepatitis guideline · EASL–ERN Wilson disease guideline

Exam words

  • 75% female predominance [IM Dept Q1]
  • Raised IgG/gamma globulins [IM Mid Q19/Q23 · IM Dept Q5]
  • type 1 ANA/SMA [IM Mid Q2 · IM Dept Q3]
  • anti-LKM1 targeting CYP2D6 [IM Dept Q2/Q4]
  • Interface hepatitis with plasma cells or piecemeal necrosis and portal fibrosis [IM Mid Q10 · IM Dept Q6]
  • Marked ALP predominance [IM Mid Q13]
  • AMA [IM Mid Q6]
  • azathioprine as steroid-sparing maintenance [IM Dept Q7–8]
  • 2–3 years of biochemical remission [IM Dept Q9–10]
  • autosomal recessive [IM Mid Q7]
  • intestinal iron absorption [IM Mid Q16]
  • skin pigmentation and diabetes [IM Mid Q18]
  • transferrin saturation and ferritin [IM Mid Q3/Q18]
  • ATP7B on chromosome 13 [IM Mid Q22/Q24]
  • defective biliary copper excretion [IM Mid Q9/Q15/Q20]
  • Kayser–Fleischer rings [IM Mid Q4/Q8/Q21]
  • Coombs-negative hemolysis through oxidative damage [IM Mid Q5]
  • low ceruloplasmin [IM Mid Q14]
  • Quantitative hepatic copper [IM Mid Q1]

Practice questions

Rapid revision sheet

Sixty-second recall. Say the definition, the key clue and the next clinical step out loud before checking the list.

  • 75% female predominance [IM Dept Q1]
  • Raised IgG/gamma globulins [IM Mid Q19/Q23 · IM Dept Q5]
  • type 1 ANA/SMA [IM Mid Q2 · IM Dept Q3]
  • anti-LKM1 targeting CYP2D6 [IM Dept Q2/Q4]
  • Interface hepatitis with plasma cells or piecemeal necrosis and portal fibrosis [IM Mid Q10 · IM Dept Q6]
  • Marked ALP predominance [IM Mid Q13]

Official College Textbook – Digestive Disorders – Part 2, pp. 115–130

Active recall

What combination supports autoimmune hepatitis in an adult with raised aminotransferases?

Increased IgG, appropriate antibody findings and compatible liver histology support the diagnosis after excluding competing causes, including drugs and viral hepatitis.

Official College Textbook – Digestive Disorders – Part 2, pp. 115–130

Recall the diagnostic and management pathway from memory.

Start with the presenting clue, name the first assessment, then distinguish confirmation, immediate management and follow-up.

  • Identify hepatitic or cholestatic injury → assess acuity, synthesis and exposures
  • Order cause-directed IgG/antibodies, iron studies or copper/genetics → use biopsy/imaging when appropriate
  • Treat confirmed cause and monitor response/toxicity
  • Decompensation or acute failure → urgent specialist and transplant assessment
↑